Interferons and Their Use in Persistent Viral Infections

  • Stéphane Chevaliez
  • Jean-Michel PawlotskyEmail author
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 189)

In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindenmann. Subsequently, the IFN-α gene was cloned, fully sequenced and IFN-α was produced in recombinant form. Recombinant IFN-α is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections.


Sustained Virological Response Sustained Virological Response Rate Adefovir Dipivoxil Persistent Viral Infection Lamivudine Monotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. (1997) National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26:2S–10SGoogle Scholar
  2. (1999) EASL International Consensus Conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol 31 Suppl 1:3–8Google Scholar
  3. (2002) National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10–12, 2002. Hepatology 36:S3–S20Google Scholar
  4. Afdhal NH, O'Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P, Lawitz E, Bzowej N, Rustgi V, Sulkowski M, Sherman KE, Jacobson I, Chao G, Knox S, Pietropaolo K, Brown N (2006) Valopicitabine (NM283), alone or with peg-interferon, compared to peg-interferon/ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior non-response to PEGIFN/RBV: week 24 results. J Hepatol 44 Suppl 2:S19CrossRefGoogle Scholar
  5. Akarca US, Ersoz G, Gunsar F, Karasu Z, Saritas E, Yuce G, Batur Y (2004) Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 9:325–334PubMedGoogle Scholar
  6. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80:4501–4509PubMedCrossRefGoogle Scholar
  7. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM (2006) A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44:671–678PubMedCrossRefGoogle Scholar
  8. Bain VG, Marotta P, Kaita K, Yoshida E, Swain MG, Bailey R, Neumann AU, Cronin PW, McHutchison JG, Pulkstenis E, Subramanian GM (2007) Comparable antiviral response rates with albumin interferon alpha-2b dosed at Q2W or Q4W intervals in naive subjects with genotype 2 or 3 chronic hepatitis C. J Hepatol 46:S7CrossRefGoogle Scholar
  9. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 11:35–45PubMedGoogle Scholar
  10. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, Barbarini G (1999) Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Scand J Gastroenterol 34:928–933PubMedCrossRefGoogle Scholar
  11. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri S, Annese M, Matarazzo F, Di Stefano G, Barbarini G (2001) Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 35:406–411PubMedCrossRefGoogle Scholar
  12. Blatt LM, Davis JM, Klein SB, Taylor MW (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16:489–499PubMedGoogle Scholar
  13. Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, Mudter J, Lohr HF, Galle PR (2006) Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int 26:319–325PubMedCrossRefGoogle Scholar
  14. Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749–795PubMedCrossRefGoogle Scholar
  15. Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, Crivellaro C, Vergani GM, Iorio R, Pace M, Con P, Gatta A (2000) Long term effect of alpha interferon in children with chronic hepatitis B. Gut 46:715–718PubMedCrossRefGoogle Scholar
  16. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107:812–817PubMedGoogle Scholar
  17. Brockmeyer NH, Poffhoff A, Bader A, Hochdorfer B, Schlottmann R, Rasokat H, Altmeyer P, Kreuter A (2006) Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients. Eur J Med Res 11:27–32PubMedGoogle Scholar
  18. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlère M, Renou C, Tran A, Melin P, Hézode C, Chevallier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM (2006) Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2a plus ribavirin combination. Gastroenterology 131:1339–1341CrossRefGoogle Scholar
  19. Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P (2007) Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res 73:118–125PubMedCrossRefGoogle Scholar
  20. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, Quaglia S, De Blasi T, Romano P, Traverso A, Leo G, Carbone R, Del Mastro B, Tinelli M, Caramello P, Di Perri G (2007) A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 14:116–121PubMedCrossRefGoogle Scholar
  21. Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, Sut N, Ozaras R, Midilli K, Ozbay G (2006) Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hep-atol 21:657–663CrossRefGoogle Scholar
  22. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC (1989) Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588–591PubMedCrossRefGoogle Scholar
  23. Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jimenez FJ, Quiroga JA (1999) Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. Hepatology 30:277–282PubMedCrossRefGoogle Scholar
  24. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, Pham BN, Maylin S, Bedossa P, Deny P, Marcellin P, Gault E (2006) Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 44:728–735PubMedCrossRefGoogle Scholar
  25. Castro A, Suarez D, Inglada L, Carballo E, Dominguez A, Diago M, Such J, Del Olmo JA, Perez-Mota A, Pedreira J, Quiroga JA, Carreno V (1997) Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res 17:27–30PubMedGoogle Scholar
  26. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ (2005a) Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 41:1357–1364CrossRefGoogle Scholar
  27. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, Chan FK, Hung LC, Lee YT, Tam JS, Lam CW, Sung JJ (2005b) A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142:240–250Google Scholar
  28. Chang CC, Chen TT, Cox BW, Dawes GN, Stemmer WP, Punnonen J, Patten PA (1999) Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 17:793–797PubMedCrossRefGoogle Scholar
  29. Chen J, Baig E, Fish EN (2004) Diversity and relatedness among the type I interferons. J Interferon Cytokine Res 24:687–698PubMedGoogle Scholar
  30. Clemens MJ (2003) Interferons and apoptosis. J Interferon Cytokine Res 23:277–292PubMedCrossRefGoogle Scholar
  31. Coccia EM, Krust B, Hovanessian AG (1994) Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. J Biol Chem 269:23087–23094PubMedGoogle Scholar
  32. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N (2003) Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10:298–305PubMedCrossRefGoogle Scholar
  33. Creagh EM, O'Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that cooperate in innate immunity. Trends Immunol 27:352–357PubMedCrossRefGoogle Scholar
  34. Dash S, Prabhu R, Hazari S, Bastian F, Garry R, Zou W, Haque S, Joshi V, Regenstein FG, Thung SN (2005) Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation. Liver Int 25:580–594PubMedCrossRefGoogle Scholar
  35. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodes J, Rosenberg W, Valla D (2003) EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 39 Suppl 1:S3–S25PubMedCrossRefGoogle Scholar
  36. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Veronese L, Raiteri R, Calleri G, Di Perri G (2006) The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b. Antivir Ther 11:165–171PubMedGoogle Scholar
  37. Di Bisceglie A (1997) Hepatitis D virus. Marcel Dekker, NYGoogle Scholar
  38. Di Bisceglie AM, Hoofnagle JH (2002) Optimal therapy of hepatitis C. Hepatology 36:S121–S127PubMedGoogle Scholar
  39. Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JH (1986) Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology 90: 150–157PubMedGoogle Scholar
  40. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44:896–906PubMedCrossRefGoogle Scholar
  41. Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC (2003) Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 370:391–396PubMedCrossRefGoogle Scholar
  42. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC (2004) Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279: 32269–32274PubMedCrossRefGoogle Scholar
  43. Ealick Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE (1991) Three-dimensional structure of recombinant human interferon-gamma. Science 252:698–702PubMedCrossRefGoogle Scholar
  44. Emilie D, Burgard M, Lascoux-Combe C, Laughlin M, Krzysiek R, Pignon C, Rudent A, Molina JM, Livrozet JM, Souala F, Chene G, Grangeot-Keros L, Galanaud P, Sereni D, Rouzioux C (2001) Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 15:1435–1437PubMedCrossRefGoogle Scholar
  45. Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Jomura H, Habu D, Sakaguchi H, Takeda T, Kawada N, Seki S, Shiomi S, Koh N, Nishiguchi S (2007) Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res 27:201–207PubMedCrossRefGoogle Scholar
  46. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, Heintges T, Haussinger D (2006) Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 26:805–810PubMedCrossRefGoogle Scholar
  47. Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, Caruso L, Scaccabarozzi S, Criscuolo D et al (1994) Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 330:88–94PubMedCrossRefGoogle Scholar
  48. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, Serra G, Lai ME, Loy M, Caruso L, Desmet V, Purcell RH, Balestrieri A (2004) Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126:1740–1749PubMedCrossRefGoogle Scholar
  49. Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW (1998) Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 93:896–900PubMedCrossRefGoogle Scholar
  50. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW (2000) Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 46:420–426PubMedCrossRefGoogle Scholar
  51. Fernandez-Cruz E, Lang JM, Frissen J, Furner V, Chateauvert M, Boucher CA, Dowd P, Stevens J (1995) Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 × 10(6)/L: results of the Zidon trial. AIDS 9:1025–1035Google Scholar
  52. Fernie BF, Poli G, Fauci AS (1991) Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J Virol 65:3968–3971PubMedGoogle Scholar
  53. Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, Holden-Wiltse J, Meehan PM (1997) Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol 16:247–253PubMedGoogle Scholar
  54. Flink HJ, Hansen BE, Heathcote EJ, Feinman SV, Simsek H, Karayalcin S, Mach T, Leemans WF, de Man RA, Verhey E, Schalm SW, Janssen HL (2006a) Successful treatment with peginter-feron alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 101:2523–2529CrossRefGoogle Scholar
  55. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL (2006b) Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101:297–303CrossRefGoogle Scholar
  56. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R (2002) Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35:694–703PubMedCrossRefGoogle Scholar
  57. Fried M, Jensen D, Rodriguez-Torres M, Nyberg L, Di Bisceglie A, Morgan T, Pockros PJ, Lin A, Cupelli L, Nelson D (2006) Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (RBV) (Copegus) in patients with “difficult-to-treat” characteristics. Hepatology 44 Suppl 1:314AGoogle Scholar
  58. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982PubMedCrossRefGoogle Scholar
  59. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU (2007) TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446:916–920PubMedCrossRefGoogle Scholar
  60. Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, Sagnelli E, Brunetto MR, Rizzetto M (2000) Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 32:824–827PubMedCrossRefGoogle Scholar
  61. Gale M Jr, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436:939–945PubMedCrossRefGoogle Scholar
  62. Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, Bonino F, Rizzetto M, Verme G, Craxi A et al (1994) Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 14:154–157PubMedGoogle Scholar
  63. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R (2006a) Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Clin Ter 157:377–386Google Scholar
  64. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R (2006b) Interferon-gamma: biologic functions and HCV therapy (type I/II) (2 of 2 parts). Clin Ter 157:457–468Google Scholar
  65. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C (1995) The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 15:45–52PubMedGoogle Scholar
  66. Gendelman HE, Baca LM, Turpin J, Kalter DC, Hansen B, Orenstein JM, Dieffenbach CW, Friedman RM, Meltzer MS (1990) Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol 145:2669–26676PubMedGoogle Scholar
  67. Giovannini M, Zuccotti GV, Biasucci G, Locatelli V, Riva E (1992) Combined zidovudine and interferon-alpha 2a therapy in children with acquired immune deficiency syndrome. J Int Med Res 20:295–301PubMedGoogle Scholar
  68. Gorbakov VV, Kim H, Oronsky B, Lang W (2005) HCV RNA results from a Phase II, randomized, open-labeled study of omega interferon (IFN) with or without ribavirin in IFN-naive genotype 1 chronic HCV patients. Hepatology 42:705AGoogle Scholar
  69. Gough DJ, Sabapathy K, Ko EY, Arthur HA, Schreiber RD, Trapani JA, Clarke CJ, Johnstone RW (2007) A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes. J Biol Chem 282:938–946PubMedCrossRefGoogle Scholar
  70. Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91PubMedCrossRefGoogle Scholar
  71. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, Ilter T, Batur Y (2005) Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 10:721–726PubMedGoogle Scholar
  72. Habersetzer F, Boyer N, Marcellin P, Bailly F, Ahmed SN, Alam J, Benhamou JP, Trepo C (2000) A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver 20:437–441PubMedCrossRefGoogle Scholar
  73. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355PubMedGoogle Scholar
  74. Hansen BD, Nara PL, Maheshwari RK, Sidhu GS, Bernbaum JG, Hoekzema D, Meltzer MS, Gendelman HE (1992) Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. J Virol 66:7543–7548PubMedGoogle Scholar
  75. Hayden MS, West AP, Ghosh S (2006) NF-kappaB and the immune response. Oncogene 25: 6758–6780PubMedCrossRefGoogle Scholar
  76. Hezode C, Bouvier-Alias M, Roudot-Thoraval F, Zafrani S, Dhumeaux D, Mallat A, Pawlotsky JM (2006) Efficacy and safety of peginterferon alpha-2a administrated every five days in combination with ribavirin in HCV genotype 1-infected patients with severe fibrosis not responding to weekly administrations of peginterferon in combination with ribavirin. Hepatology 44:322AGoogle Scholar
  77. Ho DD, Hartshorn KL, Rota TR, Andrews CA, Kaplan JC, Schooley RT, Hirsch MS (1985) Re-combinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 1:602–604PubMedCrossRefGoogle Scholar
  78. Hodson EM, Jones CA, Strippoli GF, Webster AC, Craig JC (2007) Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD005129Google Scholar
  79. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772–777PubMedCrossRefGoogle Scholar
  80. Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S (2007) Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126:245–249PubMedCrossRefGoogle Scholar
  81. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315:1575–1578PubMedGoogle Scholar
  82. Horiike N, Onji M (2003) Combination therapy with interferon-alpha and ribavirin as im-munomodulators in patients with chronic hepatitis C. J Gastroenterol 38:302–304PubMedCrossRefGoogle Scholar
  83. Hui CK, Lai LS, Lam P, Zhang HY, Fung TT, Lai ST, Wong WM, Lo CM, Fan ST, Leung N, Lau GK (2006) 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection. Aliment Pharmacol Ther 23:1171–1178PubMedCrossRefGoogle Scholar
  84. Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147:258–267PubMedGoogle Scholar
  85. Isomura S, Ichikawa T, Miyazu M, Naruse H, Shibata M, Imanishi J, Matsuo A, Kishida T, Karaki T (1982) The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken J 25:131–137PubMedGoogle Scholar
  86. Jacobson IM, Brown RS, Freilich B, Afdhal N, Kwo P, Santoro J, Becker S, Wakil A, Pound D, Godofsky E, Staruss R, Bernstein D, Flamm S, Bala N, Araya V, Davis M, Monsour H, Vierling J, Regenstein F, Balan V, Dragutsky M, Epstein M, Herring RW, Rubin R, Galler G, Pauly MP, Griffel LH, Brass CA (2005) Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community-based trial. Hepatology 42 Suppl 1:749AGoogle Scholar
  87. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345:1452–1457PubMedCrossRefGoogle Scholar
  88. Jang MK, Chung YH, Choi MH, Kim JA, Ryu SH, Shin JW, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ (2004) Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 19:1363–1368PubMedCrossRefGoogle Scholar
  89. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW (2005) Pegylated in-terferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123–129PubMedCrossRefGoogle Scholar
  90. Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G (2002) Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 72:349–361PubMedCrossRefGoogle Scholar
  91. Jen JF, Glue P, Gupta S, Zambas D, Hajian G (2000) Population pharmacokinetic and pharmacody-namic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 22:555–565PubMedCrossRefGoogle Scholar
  92. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B (2006) Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43:954–960PubMedCrossRefGoogle Scholar
  93. Kagawa T, Morizane T, Saito H, Tsunematsu S, Tada S, Kumagai N, Tsuchimoto K, Sugiura H, Mukai M, Tsuchiya M (1993) A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B. Am J Gastroenterol 88:212–216PubMedGoogle Scholar
  94. Kalil AC, Devetten MP, Singh S, Lesiak B, Poage DP, Bargenquast K, Fayad P, Freifeld AG (2005) Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis 40:764–766PubMedCrossRefGoogle Scholar
  95. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19–28PubMedCrossRefGoogle Scholar
  96. Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, Bozaci M, Besisik F, Cakaloglu Y, Okten A (2005) Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 49:1135–1138PubMedCrossRefGoogle Scholar
  97. Kaymakoglu S, Danalioglu A, Demir K, Karaca C, Akyuz F, Onel D, Badur S, Cevikbas U, Besisik F, Cakaloglu Y, Okten A (2007a) Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B. Dig Dis Sci 52:727–731CrossRefGoogle Scholar
  98. Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersoz G, Ozenirler S, Kalayci C, Poturoglu S, Cakaloglu Y, Okten A (2007b) Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother 51:3020–3022CrossRefGoogle Scholar
  99. Keeffe EB, Hollinger FB (1997) Therapy of hepatitis C: consensus interferon trials. Hepatology 26:101S–107SPubMedCrossRefGoogle Scholar
  100. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4:936–962PubMedCrossRefGoogle Scholar
  101. Kim KI, Sasase N, Taniguchi M, Mita K, Kinoshita K, Togitani T, Shikata M, Kimura N, Izawa S, Ohtani A, Nakao K, Muramoto Y, Kim SR, Nabeshima S, Ishii F, Tanaka K, Hayashi Y (2005) Interferon-beta induction/interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Int J Clin Pharmacol Res 25:71–76PubMedGoogle Scholar
  102. Kozlowski A, Charles SA, Harris JM (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15:419–429PubMedCrossRefGoogle Scholar
  103. Krown SE, Aeppli D, Balfour HH Jr (1999) Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 20:245–254PubMedGoogle Scholar
  104. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA (2001) Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276:39765–39771PubMedCrossRefGoogle Scholar
  105. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, Clementi M, Colombo M (1997) A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26:1621–1625PubMedCrossRefGoogle Scholar
  106. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M (2003) Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37:756–763PubMedCrossRefGoogle Scholar
  107. Lane HC (1994) Interferons in HIV and related diseases. AIDS 8 Suppl 3:S19–S23PubMedCrossRefGoogle Scholar
  108. Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, Notvall L, Bigger C (2003) Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic repli-cons. J Virol 77:1092–1104PubMedCrossRefGoogle Scholar
  109. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH (1997) Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113:1660–1667PubMedCrossRefGoogle Scholar
  110. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH (1998) 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 28:1121–1127PubMedCrossRefGoogle Scholar
  111. Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, Hoofnagle JH (1999a) Lamivudine for chronic delta hepatitis. Hepatology 30:546–549CrossRefGoogle Scholar
  112. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH (1999b) Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology 117:1229–1233CrossRefGoogle Scholar
  113. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N (2005) Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682–2695PubMedCrossRefGoogle Scholar
  114. Leemans WF, Flink HJ, Janssen HL, Niesters HG, Schalm SW, de Man RA (2006) The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 44:507–511PubMedCrossRefGoogle Scholar
  115. Lewis M, Amsden JR (2007) Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. Pharmacotherapy 27:455–458PubMedCrossRefGoogle Scholar
  116. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M (2005) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25:472–489PubMedCrossRefGoogle Scholar
  117. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46:45–52PubMedCrossRefGoogle Scholar
  118. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R (2005) High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 41:275–279PubMedCrossRefGoogle Scholar
  119. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395–403PubMedCrossRefGoogle Scholar
  120. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45:507–539PubMedCrossRefGoogle Scholar
  121. Lok AS, Chung HT, Liu VW, Ma OC (1993) Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105:1833–1838PubMedGoogle Scholar
  122. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V (1994) Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 19:1331–1336PubMedGoogle Scholar
  123. Manesis EK, Hadziyannis SJ (2001) Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121:101–109PubMedCrossRefGoogle Scholar
  124. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with in-terferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965PubMedCrossRefGoogle Scholar
  125. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206–1217PubMedCrossRefGoogle Scholar
  126. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131:1887–1898PubMedCrossRefGoogle Scholar
  127. Martal JL, Chene NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, Charlier MA, Charpigny SY (1998) IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 80:755–777PubMedCrossRefGoogle Scholar
  128. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492PubMedCrossRefGoogle Scholar
  129. McHutchison JG, Shiffman ML, Gordon SC, Lindsay KL, Morgan T, Norkrans G, Esteban-Mur R, Poynard T, Pockros PJ, Albrecht JK, Brass C (2006) Sustained virologic response (SVR) to interferon-alpha-2b+/− ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up. J Hepatol 44 Suppl 2:S275CrossRefGoogle Scholar
  130. McHutchison JG, Everson GT, Gordon S, Jacobson I, Kauffman R, McNair L, Muir AJ (2007a) Results of an interim analysis of a Phase II study of telaprevir (VX-950) with peginterferon alfa-2a and ribavirin in previously untreated subjects with hepatitis C. J Hepatol 46:S296CrossRefGoogle Scholar
  131. McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML, Wong JB (2007b) Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 102:880–889CrossRefGoogle Scholar
  132. Miglioresi L, Bacosi M, Russo F, Patrizi F, Saccenti P, Ursitti A, Angelis AD, Ricci GL (2003) Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res 27:253–259PubMedCrossRefGoogle Scholar
  133. Montalto G, Tripi S, Cartabellotta A, Fulco M, Soresi M, Di Gaetano G, Carroccio A, Levrero M (1998) Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am J Gastroenterol 93:950–953PubMedGoogle Scholar
  134. Moskovitz DN, Manoharan P, Heathcote EJ (2003) High dose consensus interferon in nonrespon-ders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol 17: 479–482PubMedGoogle Scholar
  135. Munoz R, Castellano G, Fernandez I, Alvarez MV, Manzano ML, Marcos MS, Cuenca B, Solis-Herruzo JA (2002) A pilot study of beta-interferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon. J Hepatol 37:655–659PubMedCrossRefGoogle Scholar
  136. Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsodi J, Boll W, Cantell K, Weissmann C (1980) Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature 284:316–320PubMedCrossRefGoogle Scholar
  137. Nakajima H, Shimomura H, Iwasaki Y, Ikeda F, Umeoka F, Chengyu P, Taniguchi H, Ohnishi Y, Takagi SJ, Fujioka S, Shiratori Y (2003) Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin. Acta Med Okayama 57:217–225PubMedGoogle Scholar
  138. Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, Kottilil S (2007) Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 21:1855–1865PubMedCrossRefGoogle Scholar
  139. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422–1427PubMedCrossRefGoogle Scholar
  140. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, Fontana R, Little N, Campbell F, Smedile A, Manns MP, Andriulli A, Rizzetto M (2005a) Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 22: 227–232CrossRefGoogle Scholar
  141. Niro GA, Rosina F, Rizzetto M (2005b) Treatment of hepatitis D. J Viral Hepat 12:2–9CrossRefGoogle Scholar
  142. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, Stanzione M, David E, Bran-caccio G, Fontana R, Perri F, Andriulli A, Rizzetto M (2006) Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44: 713–720PubMedCrossRefGoogle Scholar
  143. Novozhenov V, Zakharova N, Vinogradova E, Nikitin I, Gorbakov VV, Yakovlev A, Pak S, Rafalski V, Bogomolov P, Alessi T, Blanchett D, Lang W, Langecker P, McNally J, McHutchison JG (2007) Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection. J Hepatol 46:S8CrossRefGoogle Scholar
  144. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T (2007) Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282:7576–7581PubMedCrossRefGoogle Scholar
  145. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303:540–548PubMedCrossRefGoogle Scholar
  146. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW (1992) A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 12:55–59PubMedGoogle Scholar
  147. Papatheodoridis GV, Manesis E, Hadziyannis SJ (2001) The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34:306–313PubMedCrossRefGoogle Scholar
  148. Parvez MK, Sehgal D, Sarin SK, Basir SF, Jameel S (2006) Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol 12:3006–3014PubMedGoogle Scholar
  149. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L (1992) Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 14:221–225PubMedCrossRefGoogle Scholar
  150. Pawlotsky JM (2006) Therapy of hepatitis C: from empiricism to eradication. Hepatology 43:S207–S220PubMedCrossRefGoogle Scholar
  151. Pawlotsky JM, Chevaliez S, McHutchison JG (2007) The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132:1979–1998PubMedCrossRefGoogle Scholar
  152. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L, Dhumeaux D (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:703–714PubMedCrossRefGoogle Scholar
  153. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M (2007) Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919–922PubMedCrossRefGoogle Scholar
  154. Pestka S, Langer JA, Zoon KC, Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56:727–777PubMedCrossRefGoogle Scholar
  155. Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8–32PubMedCrossRefGoogle Scholar
  156. Peters M, Walling DM, Kelly K, Davis GL, Waggoner JG, Hoofnagle JH (1986) Immunologic effects of interferon-alpha in man: treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol 137:3147–3152PubMedGoogle Scholar
  157. Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DA, Freestone DS, Shepherd WM (1984) Intranasal lymphoblastoid interferon (“Wellferon”) prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 4:535–541PubMedGoogle Scholar
  158. Plauth MM, Meisel H, Langecker P, Moran M, Lang W, Blanchett D, Jetschmann JU, Brack J, von Wussow P (2002) Open-labeled study of omega interferon in previously untreated HCV-infected patients. In: Proceedings of the 37th annual meeting EASLGoogle Scholar
  159. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS (1989) Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244:575–577PubMedCrossRefGoogle Scholar
  160. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426–1432PubMedCrossRefGoogle Scholar
  161. Rahal JJ, Anderson J, Rosenberg C, Reagan T, Thompson LL (2004) Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis 190:1084–1087PubMedCrossRefGoogle Scholar
  162. Rodriguez-Torres M, Lawitz E, Muir AJ, Keane J, Kieffer TL, McNair L, McHutchison JG (2006) Current status of subjects receiving peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), PEG-IFN and RBV. Hepatology 44 Suppl 2:532AGoogle Scholar
  163. Rosina F, Pintus C, Meschievitz C, Rizzetto M (1991) A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 13:1052–1056PubMedCrossRefGoogle Scholar
  164. Sainz B Jr, Mossel EC, Peters CJ, Garry RF (2004) Interferon-beta and interferon-gamma syner-gistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329:11–17PubMedCrossRefGoogle Scholar
  165. Santantonio T, Niro GA, Sinisi E, Leandro G, Insalata M, Guastadisegni A, Facciorusso D, Gravinese E, Andriulli A, Pastore G (2002) Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 36:799–804PubMedCrossRefGoogle Scholar
  166. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Francavilla R, Pastore G (2005) Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 42:329–333PubMedCrossRefGoogle Scholar
  167. Saracco G, Rosina F, Brunetto MR, Amoroso P, Caredda F, Farci P, Piantino P, Bonino F, Rizzetto M (1987) Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. J Hepatol 5:274–281PubMedCrossRefGoogle Scholar
  168. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC (2005) Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 100:2463–2471PubMedCrossRefGoogle Scholar
  169. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC, Konar A, Chawla YK, Jain RK, Nanda V, Kumar A, Hissar S, Lavate P, Lahoti D (2007) Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 102:96–104PubMedCrossRefGoogle Scholar
  170. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink CJ, Reesink HW, Zeuzem S, Kwong AD (2007) Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950). Gastroenterology 132:1767–1777PubMedCrossRefGoogle Scholar
  171. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, Clementi M, Dianzani F, Antonelli G (2004) Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 9:1003–1011PubMedGoogle Scholar
  172. Seth RB, Sun L, Chen ZJ (2006) Antiviral innate immunity pathways. Cell Res 16:141–147PubMedCrossRefGoogle Scholar
  173. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4:63–68PubMedCrossRefGoogle Scholar
  174. Shi M, Wang RS, Zhang H, Zhu YF, Han B, Zhang Y, Jin LJ, Yang ZJ, Xu YP (2006) Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 58:1031–1035PubMedCrossRefGoogle Scholar
  175. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matsumura M, Narita T, Kawada K, Omata M (2000) High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. Dig Dis Sci 45:2414–2421PubMedCrossRefGoogle Scholar
  176. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705–706PubMedCrossRefGoogle Scholar
  177. Sjogren MH, Sjogren R Jr, Lyons MF, Ryan M, Santoro J, Smith C, Reddy KR, Bonkovsky H, Huntley B, Faris-Young S (2007) Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci 52:1540–1547PubMedCrossRefGoogle Scholar
  178. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K (2006) Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 62:699–709PubMedCrossRefGoogle Scholar
  179. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J (2006) Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol 72:1469–1476PubMedCrossRefGoogle Scholar
  180. Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, Thuy TT, Loan HT, Khanh VC, Vaughn DW, White NJ, Farrar JJ (2003) Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 361:821–826PubMedCrossRefGoogle Scholar
  181. Soza A, Heller T, Ghany M, Lutchman G, Jake Liang T, Germain J, Hsu HH, Park Y, Hoofnagle JH (2005) Pilot study of interferon gamma for chronic hepatitis C. J Hepatol 43:67–71PubMedCrossRefGoogle Scholar
  182. Swain MG, Lai MY, Shiffman ML, Cooksley WGE, Abergel A, Lin A, Connell E, Diago M (2007) Durable sustained virological response after treatment with peginterferon alfa-2a (Pegasys) alone or in combination with ribavirin (Copegus): 5-year follow-up and the criteria for a cure. J Hepatol 46 Suppl 1:S3CrossRefGoogle Scholar
  183. Takaoka A, Yanai H (2006) Interferon signalling network in innate defence. Cell Microbiol 8: 907–922PubMedCrossRefGoogle Scholar
  184. Uematsu S, Akria S (2007) Toll-like receptors and type I interferons. J Biol Chem 282: 15319–15323PubMedCrossRefGoogle Scholar
  185. Uze G, Monneron D (2007) IL-28 and IL-29: newcomers to the interferon family. Biochimie 89:729–734PubMedCrossRefGoogle Scholar
  186. van der Ende M, Mulder JW, van den Berge M, Blok W, Schutten M (2007) Complete clinical and virological remission of refractory HIV-related Kaposi's sarcoma with pegylated interferon alpha. AIDS 21:1661–1662PubMedCrossRefGoogle Scholar
  187. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, Schalm SW, Janssen HL (2004) Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39:804–810PubMedCrossRefGoogle Scholar
  188. van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL (2006) Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 26:399–405PubMedCrossRefGoogle Scholar
  189. Vassiliadis T, Tziomalos K, Patsiaoura K, Zagris T, Giouleme O, Soufleris K, Grammatikos N, Theodoropoulos K, Mpoumponaris A, Dona K, Zezos P, Nikolaidis N, Orfanou-Koumerkeridou E, Balaska A, Eugenidis N (2007) Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. J Gastroenterol Hepatol 22:1582–1588PubMedCrossRefGoogle Scholar
  190. Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F (1996) Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. Dig Dis Sci 41:1241–1247PubMedCrossRefGoogle Scholar
  191. Villano SA, Raible D, Harper D, Speth J, Chandra P, Shaw P, Bichier G (2007) Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pagylated interferon alfa-2b in treatment-naive patients with chronic HCV. J Hepatol 46:S24CrossRefGoogle Scholar
  192. Wang T, Blatt LM, Seiwert SD (2006) Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections. J Interferon Cytokine Res 26:473–483PubMedCrossRefGoogle Scholar
  193. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM, Dooley S (2005) Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 3:819–828PubMedCrossRefGoogle Scholar
  194. Wheelock EF, Sibley WA (1965) Circulating virus, interferon and antibody after vaccination with the 17-D strain of yellow-fever virus. N Engl J Med 273:194–198PubMedCrossRefGoogle Scholar
  195. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP (2006) Early monotherapy with pegy-lated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43:250–256PubMedCrossRefGoogle Scholar
  196. Wolters LM, van Nunen AB, Honkoop P, Vossen AC, Niesters HG, Zondervan PE, de Man RA (2000) Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 7:428–434PubMedCrossRefGoogle Scholar
  197. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312–323PubMedGoogle Scholar
  198. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J (2006) Pegin-terferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44:675–684PubMedCrossRefGoogle Scholar
  199. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5:730–737PubMedCrossRefGoogle Scholar
  200. Yurdaydin C, Bozkaya H, Cetinkaya H, Sahin T, Karaoguz D, Toruner M, Erkan O, Heper AO, Erden E, Bozdayi AM, Uzunalimoglu O (2005) Lamivudine vs lamivudine and interferon combination treatment of HBeAg(−) chronic hepatitis B. J Viral Hepat 12:262–268PubMedCrossRefGoogle Scholar
  201. Yurdaydin C, Wedemeyer H, Dalekos G, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Bock T, Manns MP (2006) A multicenter randomized study comparing the efficacy of pegylated interferon-alpha-2a plus adefovir dipivoxil versus pegyated interferon-alpha-2a plus placebo versus adefovir dipivoxil for the treatment of chronic hepatitis delta hepatitis: the HEP-NET/International Delta Hepatitis Intervention Trial (HID-IT). Hepatology 44:230AGoogle Scholar
  202. Zeuzem S, Benhamou Y, Bain V, Shouval D, Pianko S, Flisiak R, Grigorescu M, Rehak V, Yoshida E, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG (2007) Antiviral response at week 12 following completion of treatment with Albinterferon alpha-2b plus ribavirin in genotype 1, IFN-naive, chronic hepatitis patients. J Hepatol 46:S293CrossRefGoogle Scholar
  203. Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, Wei L, Wang GQ, Tanaka Y, Mizokami M, Si CW (2007) Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 44:541–548PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of VirologyHôpital Henri MondorFrance

Personalised recommendations